Factors affecting early molecular response in chronic myeloid leukemia
. Clinical Limphoma Myeloma &Leukemia, 15: 114-119 (2015).
As reported by Marin et al various factors affect adherence in chronic myeloid leukemia
patients, including lower age group, adverse effects of TKI therapy, psychological differences among patients and perception about disease15.
Kochupillai, "Pigmentary changes in chronic myeloid leukemia
patients treated with imatinib mesylate," Annals of Oncology, vol.
Druker, "Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia
in pregnancy," Obstetrics & Gynecology, vol.
Eighty percent of these are acute lymphoblastic leukemia (ALL), 17% are acute myeloid leukemia (AML) and the rest are cases of chronic myeloid leukemias
It is concluded that in CMPD, Chronic Myeloid Leukemia
is commonest and Essential Thrombocythemia was least common.
Nilotinib as front-line treatment for patients with chronic myeloid leukemia
in early chronic phase.
Miranda et al., "EUTOS score is predictive of event-free survival, but not for progression-free and overall survival in patients with early chronic phase chronic myeloid leukemia
treated with imatinib: a single institution experience," Blood, vol.
Tono et al., "Leukostasis in children and adolescents with chronic myeloid leukemia
: Japanese Pediatric Leukemia/Lymphoma Study Group," Pediatric Blood and Cancer, vol.
Kajtar, "Outcome of 3 pregnancies in a patient with chronic myeloid leukemia
who received 3 types of tyrosine kinase inhibitors each in different pregnancy: followup of the case with a review of published reports," Annals of Saudi Medicine, vol.
Cortes, "Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
: an evolving treatment paradigm," Clinical Lymphoma Myeloma & Leukemia, vol.
Sessions (2007) stated that chronic myeloid leukemia
is a stem cell cancer and represents 15-20% of all adult leukemia diagnosed each year.